A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Pretomanid (Primary)
- Indications Tuberculosis
- Focus Pharmacokinetics
- 28 Dec 2015 Planned primary completion date changed from 1 Oct 2016 to 11 Mar 2019.
- 28 Dec 2015 Status changed from suspended to recruiting.
- 09 Oct 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov